Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment

AbbVie (prior sponsor, Abbott)52 enrolled

Overview

Psoriatic Arthritis (PsA) is a comorbidity that affects a significant proportion of participants with moderate or severe psoriasis. The purpose of this study was to describe the profile of patients with moderate or severe plaque psoriasis (Ps) in Colombia and to evaluate adalimumab efficacy and safety profile.

Psoriasis is a chronic inflammatory disease affecting 1% to 3% of the population worldwide. A significant portion (5%-40%) of participants with psoriasis develop PsA, a chronic inflammatory arthritis that causes progressive joint damage, reduced functionality and increased mortality risk. Skin disease typically manifests before arthritis in more than 80% of PsA participants, and psoriasis symptoms usually precede joint symptoms by an average of 10 years. Participants with psoriasis who have comorbid PsA incur substantially increased cost of care and experience greater impairment of physical functioning and quality of life compared with participants with psoriasis alone.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Psoriasis Psoriatic Arthritis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participant has a documented clinical diagnosis of psoriasis, as determined by participant interview of his/her medical history and confirmation of diagnosis through physical examination by the investigator * Participant has indication of psoriasis systemic therapy * If female, participant is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or is of childbearing potential and practicing one of the following methods of birth control: * Condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD) * Contraceptives (oral or parenteral) for three months (90 days) prior to study drug administration * A vasectomized partner * Total abstinence from sexual intercourse * Able and willing to give written informed consent and comply with the requirements of the study protocol Exclusion Criteria: * Participants who have active infections * Participants enrolled in another study or clinical trial * Any condition that according to the criteria of the participating investigator represents an obstacle for study conduction and/or participants to an unacceptable risk * History of active tuberculosis (TB), histoplasmosis or listeriosis

Locations (15)

Site Reference ID/Investigator# 48347

Barranquilla, Colombia

Site Reference ID/Investigator# 48349

Barranquilla, Colombia

Site Reference ID/Investigator# 53045

Barranquilla, Colombia

Outcomes

Primary Outcomes

Percentage of Participants Who Developed Psoriatic Arthritis (PsA)

A participant is said to have PsA if they meet the following criteria: 1. PsA defined by a rheumatologist; or 2. A participant with inflamed joints \>0 and CASPAR score \>=3; or 3. Participant meeting at least one of the two previous definitions.

Time frame: At Baseline, Visit 3 (month 6) and Visit 4 (month 12)

Percentage of Participants Who Developed Signs or Symptoms of PsA

Signs or symptoms were defined as mentioning at the rheumatologist visit any joint symptoms prior to or during the visit or a total number of inflamed joints greater than 0.

Time frame: At Baseline, Visit 3 (month 6) and Visit 4 (month 12)

Secondary Outcomes

Mean Time to First Occurrence of PsA Signs or Symptoms

The measure of time from Psoriasis diagnosis to the appearance of PsA signs or symptoms.

Time frame: Baseline up to Visit 4 (month 12)

Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score

The PASI score was used to measure the severity of psoriasis. It combined the assessment of the severity of lesions and the area affected into a single score ranging from 0 (no disease) to 72 (maximal disease).

Time frame: At Baseline, Visit 2 (month 2), Visit 3 (month 6) and Visit 4 (month 12)

Percentage of Participants With Comorbidities Who Did or Did Not Develop PsA

Percentage of participants with comorbidities (metabolic syndrome, hypertension, diabetes, atherosclerosis, obesity, alcohol and other associated comorbidities) was assessed.

Time frame: Baseline up to Visit 4 (month 12)

Mean Change in Quality of Life (QoL)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Site Reference ID/Investigator# 53047

Bogotá, Colombia

Site Reference ID/Investigator# 78533

Bogotá, Colombia

Site Reference ID/Investigator# 48345

Cali, Colombia

Site Reference ID/Investigator# 48346

Cali, Colombia

Site Reference ID/Investigator# 59342

Cali, Colombia

Site Reference ID/Investigator# 48342

Cartagena, Colombia

Site Reference ID/Investigator# 48348

Cartagena, Colombia

...and 5 more locations

The Short Form-36 was a self-reported questionnaire used to measure the QoL of participants in eight main health dimensions (physical functioning; bodily pain; role limitations due to physical health, personal, and emotional problems; emotional well-being; social functioning; vitality; and general health perception). The score from each health dimension was added together for a QoL score on a scale of 0 - 100; a higher score indicated a better QoL.

Time frame: At Baseline, Visit 3 (month 6) and Visit 4 (month 12)

Mean Change in ClASsification Criteria for Psoriatic ARthritis (CASPAR) Score

The CASPAR criteria permits the diagnosis of PsA in spite of low rheumatoid factor positivity. To be classified as having PsA, a participant must have inflammatory articular disease (joint, spine, entheseal) with greater than or equal to 3 of the following 5 points: evidence of psoriasis (current, history of, or family history of); psoriatic nail dystrophy; a negative RF test result; dactylitis (history of or current); and radiographic evidence of juxa-articular new bone formation. Only current psoriasis (2 points) was weighted more heavily than the other features (1 point). CASPER scores range from 1 to 6, with 6 indicating a more definitive diagnosis of PsA.

Time frame: At Baseline, Visit 3 (month 6) and Visit 4 (month 12)

Percentage of Participants With a CASPAR Score Greater Than or Equal to 3 at Each Visit to the Rheumatologist

Time frame: At Baseline, Visit 3 (month 6) and Visit 4 (month 12)

Percentage of Participants With Swollen Joint Count (SJC) and Tender Joint Count (TJC) Greater Than Zero

Pressure and joint manipulation by physical examination on 68 or 66 joints or regions (34 or 32 per body side, hip joints excluded) were assessed for TJC or SJC, respectively. Both joint tenderness and swelling were classified as present ("1"), absent ("0"), replaced ("9"), or no assessment ("NA"). The total TJC or SJC was derived as the sum of the tender and swollen joints; the range for TJC and SJC was 0 - 68 and 0 - 66, respectively; with higher scores indicating worse conditions.

Time frame: At Baseline, Visit 3 (month 6) and Visit 4 (month 12)

Percentage of Participants With Joint Symptoms

Joint symptoms were evaluated by presence or absence of peripheral arthritis, morning stiffness and participant reported joint symptoms.

Time frame: At Baseline, Visit 3 (month 6) and Visit 4 (month 12)

Incidence Rate of PsA Since Psoriasis Diagnosis

The number of new PsA cases were determined by: 1. PsA defined by a rheumatologist; or 2. A participant with inflamed joints \>0 and CASPAR score \>=3; or 3. Participant meeting at least one of the two previous definitions occurring over person time (defined as the overall sum of Psoriasis disease duration without PsA).

Time frame: Baseline up to Visit 4 (month 12)

Change in the Subject Proportion That Achieved a PASI (Psoriasis Area and Severity Index) Reduction of ≥50%

This outcome measure was not calculated.

Time frame: At Baseline, Week 24, and Week 48